Lantern Pharma/$LTRN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lantern Pharma
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
- Ticker
- $LTRN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 16
- Headquarters
- Dallas, United States
- Website
- www.lanternpharma.com
Lantern Pharma Metrics
BasicAdvanced
$6.1M
-
-$1.63
2.32
-
Price and volume
Market cap
$6.1M
Beta
2.32
52-week high
$4.34
52-week low
$0.45
Average daily volume
274K
Financial strength
Current ratio
1.957
Quick ratio
1.711
Total debt to equity
-0.012
Profitability
EBITDA (TTM)
-15.45
Management effectiveness
Return on assets (TTM)
-74.29%
Return on equity (TTM)
-400.92%
Valuation
Price to book
-1.91
Price to tangible book (TTM)
-1.91
Price to free cash flow (TTM)
-0.39
Free cash flow yield (TTM)
-256.15%
Free cash flow per share (TTM)
-1.232
Growth
Earnings per share change (TTM)
-8.58%
3-year earnings per share growth (CAGR)
7.50%
Lantern Pharma Financial Performance
Revenues and expenses
Lantern Pharma Earnings Performance
Company profitability
Upcoming events
No upcoming events
Lantern Pharma News
AllArticlesVideos
Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
Business Wire2 days ago
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Business Wire1 month ago
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.